UNSPSC 51422434: Hydrocortisone sodium succinate

This classification denotes a therapeutic hydrocortisone with the molecular formula C25H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LQB69S1Z, chemically known as 1,4-butanedioic acid (succinic acid) but more generally known as hydrocortisone sodium succinate, which bears US NIH Compound Identifier 1110. European Medicines Agency schedules Hydrocortisone sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02569MIG.

UNSPSC 51422434 Hydrocortisone sodium succinate is a Commodity code that nominally identifies a specific pharmaceutical product, but recent state and local procurement activity under this code shows minimal direct alignment with the code's primary scope. The single recent opportunity posted under this code — Seminole County, Florida's IFB60459723LAS — solicits naloxone and drug deactivation systems rather than hydrocortisone sodium succinate, indicating either a tagging error in the county's procurement system or a mismatch between the code assignment and actual purchasing need. State and local health departments and county community health agencies appear to be the primary issuing bodies exploring this code space, though the narrow recent-opportunity set limits visibility into issuing-body patterns or repeat buyers.

Geographic activity is concentrated in Florida based on the available record, with Seminole County's June 2026 posting representing the most recent documented procurement. Seminole County's IFB, with a response deadline of July 26, 2023, was structured as a competitive bid for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract included a two-year initial term with a one-year renewal option, E-Verify compliance requirements, and drug-free workplace certification, with potential FEMA funding introducing additional federal compliance obligations. The mismatch between the code's pharmaceutical focus and the actual solicitation content suggests that business development teams should verify code accuracy with issuing bodies before committing resources to pursue opportunities under this commodity code.